中智药业(03737.HK) 公布，与美国生物医药公司GABAeron签署投资协议。据此，集团将 以 代 价300万美元认购GABAeron 300万股A系列优先股，占其优先股约11.5%。此次投资，将助力推进GABAeron的GR01细胞移植治疗阿尔茨海默病临床试验的实施。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.